Multiple myeloma · 14 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pomalidomide, Dexamethasone, Pembrolizumab Variant #01 | — | R 193 014 | 28d | — | — | — | — | — |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
DECA Variant #01 | — | R 5 615 | 21d | — | — | — | — | — |
VAD and Cyclosporine Variant #01 | — | R 3 987 | 28d | — | — | — | — | — |
VAD Variant #06 | — | R 1 864 | 28d | — | — | — | — | — |
Dexamethasone monotherapy Variant #11 | — | R 1 389 | 35d | — | — | — | — | — |
Carmustine and Doxorubicin Variant #01 Partial | — | R 287 | 28d | — | — | — | — | — |
Cyclophosphamide monotherapy N/A - secondary systemic drug | — | R 60 | 28d | — | ~15.8 mo | — | — | 1 |
EDAP Partial | — | — | — | — | — | — | — | — |
Stilbamidine and Urethane Variant #01 Partial | — | — | — | — | — | — | — | — |
Placebo Partial | — | — | — | ~22.2 mo | — | — | — | 2 |
Belantamab mafodotin monotherapy Variant #01 Partial | — | — | 21d | ~11.2 mo | — | ~17 | — | 1 |
Tisagenlecleucel monotherapy Variant #01 Partial | — | — | — | — | — | — | — | — |
Urethane monotherapy Variant #01 Partial | — | — | — | — | — | — | — | — |
14 of 14 regimens shown